The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors

Autores
Nurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A.; Tsang, Hoi P.; Roberts, David J.; Polack, Fernando Pedro; Simmonds, Peter; Hedman, Klaus; Álvarez Paggi, Damián Jorge; Harvala, Heli
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect when administered early (e.g. Argentinian trial showing reduced hospitalisation) but has in general been ineffective (e.g. REMAP-CAP trial without improvement during hospitalisation). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralising antibodies, anti-spike IgG and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas emphasising initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee convalescent plasma showed significantly higher titres and avidity, being preferable for future CP-treatment.
Fil: Nurmi, Visa. University of Oxford; Reino Unido
Fil: Knight, Chanice. University of Oxford; Reino Unido
Fil: Estcourt, Lise. University of Oxford; Reino Unido
Fil: Hepojoki, Jussi. Universitat Zurich; Suiza
Fil: Lamikanra, Abigail A.. University of Oxford; Reino Unido
Fil: Tsang, Hoi P.. University of Oxford; Reino Unido
Fil: Roberts, David J.. University of Oxford; Reino Unido
Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina
Fil: Simmonds, Peter. University of Oxford; Reino Unido
Fil: Hedman, Klaus. University of Helsinki; Finlandia
Fil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Harvala, Heli. University of Helsinki; Finlandia
Materia
SARS-CoV-2
Plasma
Convalescent
Neutralization
COVID-19
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/237444
Acceder
id CONICETDig_892bee664e30c67de628f2013dd92e4d
oai_identifier_str oai:ri.conicet.gov.ar:11336/237444
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donorsNurmi, VisaKnight, ChaniceEstcourt, LiseHepojoki, JussiLamikanra, Abigail A.Tsang, Hoi P.Roberts, David J.Polack, Fernando PedroSimmonds, PeterHedman, KlausÁlvarez Paggi, Damián JorgeHarvala, HeliSARS-CoV-2PlasmaConvalescentNeutralizationCOVID-19https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect when administered early (e.g. Argentinian trial showing reduced hospitalisation) but has in general been ineffective (e.g. REMAP-CAP trial without improvement during hospitalisation). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralising antibodies, anti-spike IgG and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas emphasising initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee convalescent plasma showed significantly higher titres and avidity, being preferable for future CP-treatment.Fil: Nurmi, Visa. University of Oxford; Reino UnidoFil: Knight, Chanice. University of Oxford; Reino UnidoFil: Estcourt, Lise. University of Oxford; Reino UnidoFil: Hepojoki, Jussi. Universitat Zurich; SuizaFil: Lamikanra, Abigail A.. University of Oxford; Reino UnidoFil: Tsang, Hoi P.. University of Oxford; Reino UnidoFil: Roberts, David J.. University of Oxford; Reino UnidoFil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Simmonds, Peter. University of Oxford; Reino UnidoFil: Hedman, Klaus. University of Helsinki; FinlandiaFil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Harvala, Heli. University of Helsinki; FinlandiaOxford University Press2023-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/237444Nurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A.; et al.; The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors; Oxford University Press; Journal of Infectious Diseases; 228; 3; 3-2023; 245-2501537-6613CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1093/infdis/jiad070info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:20:32Zoai:ri.conicet.gov.ar:11336/237444instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:20:32.762CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
title The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
spellingShingle The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
Nurmi, Visa
SARS-CoV-2
Plasma
Convalescent
Neutralization
COVID-19
title_short The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
title_full The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
title_fullStr The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
title_full_unstemmed The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
title_sort The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors
dc.creator.none.fl_str_mv Nurmi, Visa
Knight, Chanice
Estcourt, Lise
Hepojoki, Jussi
Lamikanra, Abigail A.
Tsang, Hoi P.
Roberts, David J.
Polack, Fernando Pedro
Simmonds, Peter
Hedman, Klaus
Álvarez Paggi, Damián Jorge
Harvala, Heli
author Nurmi, Visa
author_facet Nurmi, Visa
Knight, Chanice
Estcourt, Lise
Hepojoki, Jussi
Lamikanra, Abigail A.
Tsang, Hoi P.
Roberts, David J.
Polack, Fernando Pedro
Simmonds, Peter
Hedman, Klaus
Álvarez Paggi, Damián Jorge
Harvala, Heli
author_role author
author2 Knight, Chanice
Estcourt, Lise
Hepojoki, Jussi
Lamikanra, Abigail A.
Tsang, Hoi P.
Roberts, David J.
Polack, Fernando Pedro
Simmonds, Peter
Hedman, Klaus
Álvarez Paggi, Damián Jorge
Harvala, Heli
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SARS-CoV-2
Plasma
Convalescent
Neutralization
COVID-19
topic SARS-CoV-2
Plasma
Convalescent
Neutralization
COVID-19
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect when administered early (e.g. Argentinian trial showing reduced hospitalisation) but has in general been ineffective (e.g. REMAP-CAP trial without improvement during hospitalisation). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralising antibodies, anti-spike IgG and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas emphasising initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee convalescent plasma showed significantly higher titres and avidity, being preferable for future CP-treatment.
Fil: Nurmi, Visa. University of Oxford; Reino Unido
Fil: Knight, Chanice. University of Oxford; Reino Unido
Fil: Estcourt, Lise. University of Oxford; Reino Unido
Fil: Hepojoki, Jussi. Universitat Zurich; Suiza
Fil: Lamikanra, Abigail A.. University of Oxford; Reino Unido
Fil: Tsang, Hoi P.. University of Oxford; Reino Unido
Fil: Roberts, David J.. University of Oxford; Reino Unido
Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina
Fil: Simmonds, Peter. University of Oxford; Reino Unido
Fil: Hedman, Klaus. University of Helsinki; Finlandia
Fil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Harvala, Heli. University of Helsinki; Finlandia
description Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect when administered early (e.g. Argentinian trial showing reduced hospitalisation) but has in general been ineffective (e.g. REMAP-CAP trial without improvement during hospitalisation). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralising antibodies, anti-spike IgG and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas emphasising initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee convalescent plasma showed significantly higher titres and avidity, being preferable for future CP-treatment.
publishDate 2023
dc.date.none.fl_str_mv 2023-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/237444
Nurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A.; et al.; The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors; Oxford University Press; Journal of Infectious Diseases; 228; 3; 3-2023; 245-250
1537-6613
CONICET Digital
CONICET
url http://hdl.handle.net/11336/237444
identifier_str_mv Nurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A.; et al.; The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors; Oxford University Press; Journal of Infectious Diseases; 228; 3; 3-2023; 245-250
1537-6613
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1093/infdis/jiad070
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842981122590375936
score 12.48226

Publicaciones similares